World leader in IgE drugs with a pipeline of therapies to treat solid cancer tumours
Location: United Kingdom, England, London
Total raised: $61.08M
Investors 5
| Date | Name | Website |
| 02.05.2022 | British Pa... | britishpat... |
| - | ALSA Ventu... | alsaventur... |
| - | 3B Future ... | 3bfuturehe... |
| - | UCL Techno... | ucltf.co.u... |
| - | Epidarex C... | epidarex.c... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 09.09.2024 | Series B | $16.35M | - |
| 02.03.2022 | Series B | $40.99M | - |
| 20.04.2020 | - | $3.73M | - |
Mentions in press and media 16
| Date | Title | Description |
| 10.09.2024 | Epsilogen Secures £12.5 Million to Propel Cancer Treatment Innovations | Epsilogen, a pioneering force in the realm of immunoglobulin E (IgE) antibodies, has successfully raised £12.5 million in a Series B funding round. This brings the total Series B financing to an impressive £43.25 million. The funds will be ... |
| 09.09.2024 | Epsilogen Closes £12.5M Series B Extension Financing | Espislogen, a London, UK-based company which specializes in the development of immunoglobulin E (IgE) antibodies to treat cancer, raised £12.5M in Series B funding. The round, which brought the total amount to £43.25M, included participatio... |
| 09.09.2024 | Epsilogen: Immunoglobulin Development Company Raises £12.5 Million (Series B) | Epsilogen – a leader in the development of immunoglobulin E (IgE) antibodies to treat cancer – announced today the completion of a £12.5 million Series B expansion financing, bringing the Series B total to £43.25 million. The funding will a... |
| 11.07.2024 | Epsilogen announces CTA approval for Phase Ib trial of MOv18 IgE in platinum-resistant ovarian cancer | Phase Ib study expected to initiate in H2 2024 Previously reported Phase I results showedMOv18 IgE to be safe and well tolerated, with evidence of anti-tumour activity LONDON, 8 July 2024 – Epsilogen, a global leader in the development of ... |
| 02.05.2024 | Epsilogen appoints Ashley Nagle as Chief Business Officer and Peter Finan as Non-Executive Chairman as part of broader company expansion | LONDON, 3 April 2024 – Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces the appointments of Ashley Nagle as Chief Business Officer(CBO) and Peter Finan as Non-Executive Chai... |
| 31.07.2023 | Epsilogen announces successful completion of first ever clinical trial of an IgE antibody; phase I data for MOv18 IgE demonstrates potential of IgE therapy in cancer | Final results of phase I study of MOv18 IgE in ovarian cancer published in Nature Communications MOv18 IgE found to be safe and well tolerated with evidence of anti-tumour activity observed |
| 02.03.2022 | Epsilogen announces completion of oversubscribed £30.75m Series B finacing | |
| 02.03.2022 | Epsilogen Announces Completion of Oversubscribed £30.75 Million ($41.20 Million) Series B Financing | Financing led by Novartis Venture Fund and joined by new investors 3B Future Health Fund, British Patient Capital, Schroders Capital and Caribou Property alongside founding investor Epidarex Capital and ALSA Ventures |
| 02.03.2022 | Epsilogen announces completion of oversubscribed £30.75 million ($41.20 million) Series B financing | Financing led by Novartis Venture Fund and joined by new investors 3B Future Health Fund, British Patient Capital, Schroders Capital and Caribou Property alongside founding investor Epidarex Capital and ALSA Ventures |
| 02.03.2022 | London-based Epsilogen nabs £30.75 million to develop antibodies for cancer treatment | London-based startup that develops novel immunoglobulin antibodies to treat cancer, Epsilogen has raised £30.75 million ($41.20 million) in oversubscribed funding. The Series B round was led by Novartis Venture Fund and joined by 3B Future ... |
Show more